What Treatments Are Available for Cancers with FGFR2 Mutations?
The treatment of cancers with FGFR2 mutations often involves targeted therapies. FGFR inhibitors, such as erdafitinib and pemigatinib, are designed to specifically target and inhibit the FGFR2 receptor, thereby blocking the aberrant signaling pathways. These inhibitors have shown promising results in clinical trials, particularly in cancers that are driven by FGFR2 mutations. Additionally, combination therapies that include FGFR inhibitors and other forms of treatment, such as chemotherapy and immunotherapy, are being explored to enhance efficacy.
